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Abstract: 
Background: Gonadal function is affected with end stage renal disease. In men the   disturbances of the 
hypothalamic–pituitary–testicular axis can be detected with only moderate reductions in the glomerular filtration 
rate.  There are many evidences that confirm the effect of testosterone on lipid metabolism in postprandial state. 
Objective: to study the relationship between low level of total testosterone and postprandial lipids in male 
patients with end stage renal disease. 
Subjects &Method: the study involved 38 male patients with end stage renal disease ( age range of 30- 60 years 
) attending the unit of kidney disease and transplantation at Baghdad Teaching Hospital , and 35 healthy subjects 
(control group ) of matching age and weight during the period from January  to march 2013. Postprandial venous 
blood was obtained for glucose, lipid profile, urea and creatinine measurement   immediately after separation of 
the serum by routine colorimetric methods  .  
The determination of androgen sex hormones (luteinizing hormone , follicle stimulating hormone , testosterone , 
and  sex hormone binding globulin ,) was done using Enzyme-Linked Immuno Sorbent Assay. (Sandwich 
assay). 
 
Results: There was a significant negative correlation between free testosterone, and postprandial triglyceride in 
both ESRD patients and control groups with a significant difference in testosterone between these two groups.  
The sex hormone binding globulin was also correlated negatively with postprandial triglyceride in the control 
group. 
 Conclusion: Decline in free testosterone level associated increased postprandial hypertriglyceridemia, which 
could, both, be considered predictors for cardiovascular disease risk factors in male patients with ESRD. 
 Key words : Postprandial hypertriglyceridemia , free testosterone, androgen dysfunction ,ESRD.  
 
Introduction: 
Chronic kidney disease is a progressive loss in renal function over a period of months or years. There are no 
specific symptoms of deterioration of kidney function. A   reduced appetite   and feeling unwell might be the 
main symptoms of kidney dysfunction. Diabetes and /or high blood pressure are the main risk factors for 
development of kidney problems . Chronic kidney disease was classified in five stages begin with stage 1, with 
mildest and causing few symptoms which progressed to severe illness with poor life expectancy in stage 5 if 
untreated. This is according to the professional guidelines classification. Creatinine levels may be normal in the 
early stages of CKD, and the condition is discovered if urinalysis shows that the kidney is allowing the loss of 
protein or red blood cells into the urine (Levin et al 2008). Eventually, kidney failure (stage 5 CKD) ensues and 
kidney replacement therapy is required (NKF-KDOQI 2002 &Johnson 2011).  
 In CKD, the secretion of hormones and the response of target tissues were affected causing endocrine 
dysfunctions. As many as 50 to 70% of men with ESRD have been reported to be hypogonadal on the basis of 
low concentrations of total and free testosterone due to  moderate reductions in the GFR  which leads  to an 
alterations of sex steroid production and metabolism 
( Karagiannis  and  Harsoulis  2005 & Albaaj et al 2006) 
Dyslipidemia is one of the important clinical features in ESRD manifested by hyper-triglyceridemia, elevated 
level of very low density lipoprotein (VLDL), high plasma concentration of lipoprotein remnants, accumulation 
of oxidized lipids and lipoproteins, low plasma HDL, cholesterol concentration and impaired HDL maturation 
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and function , while serum cholesterol and LDL cholesterol values are frequently within or below the normal 
limits (Vaziri 2006).Many studies reported that low total testosterone level is associated with an adverse lipid 
profile, which were included high TG level and low HDL-C (Agledahl et al 2008 & Page et al 2008 & Makinen 
et al 2008). 
The major finding of the recent study has shown that the administration of total testosterone has beneficial effects 
on dyslipidemia especially on TG level. Another important finding of this study was the young and middle-aged 
men with the lowest total testosterone concentrations, had the highest risk of incident dyslipidemia (Cornoldi et al 
2010). 
  
             Subjects & Methods: 
 This study included 38 male patients with ESRD of age range between 30-60 years and disease duration from 2-
19 months, who were attending kidney disease and transplantation at Baghdad Teaching Hospital during the 
period from January to march 2013. Patients with diabetes mellitus and thyroid disease were excluded from this 
study .this study also included 35 normal male volunteers of matching age and BMI who were nonsmoker; non 
alcoholics and  none ,had dyslipidemia as revealed from pervious laboratory tests . 
Ten milliliters (10ml) of venous blood were withdrawn in 3-4 hr. after meal from both patient and 
control group. Blood samples were collected in   a plain tube and centrifuged for 15 minutes at 3000rpm after 
being allowed to clot at room temperature for 30 minutes. The separated serum   was divided into aliquots and 
were stored frozen at (-20 c˚) to be used later for  estimation of androgen sex hormone , luteinizing hormone 
(LH) ,follicle stimulating  hormone (FSH) ,  testosterone ,  free testosterone, sex hormone binding globulin 
(SHBG) by Enzyme -Linked Immune Sorbent (ELISA, Sandwich Assay)  .  
While glucose, lipid profile, urea and creatinine analysis all were done immediately after separation of 
the serum by the routine colorimetric methods. Body mass index was calculated as body weight (in Kg/Sq height 
(meter).The oral consent had been taken from all patients and controls for blood collection. 
 
Statistical study: 
All results were expressed as mean± standard deviation (mean±SD). All statistical analysis was performed 
using Statistical Package for the Social Sciences (SPSS version 15.0). Independent student t-test as performed 
to assess differences between two means. Person correlation coefficient was used to determine the correlation 
between quantitative data .P value < 0.05 was considered significant (Elliott and Woodward 2007). 
Results & Discussion; 
 As shown in table 1, there is significant differences in total testosterone, ,  free testosterone  , FSH, LH 
between two groups ( p< 0 .0001) ,while  no significant  differences in SHBG (p > 0.05) can be noted.  All other 
parameters measured were significantly higher (including serum lipids, urea, and creatinine).In the present study, 
the results  were represent clearly low serum total testosterone and free testosterone in the ESRD patients relative 
to the normal controls, and this was associated with higher rise in the serum postprandial triglycerides, while 
there was no significant differences in SHBG  level between both ESRD patients  and their control group. These 
results were confirmed by the result of Albaaj et al 2006, while another study, noted that concentration of SHBG 
was elevated (  Albaaj et al 2006 & Al-Khallaf   etal 2012 ).Male hypoandrogenism i.e. low testosterone is the 
most common   gonadal dysfunction in men, mainly due to reduced prolactin clearance. A prolactin-induced 
inhibition of gonadotropin, is considered as one of the most important causes of testosterone deficiency, and has 
been reported to associate cardiovascular risk factors and mortality in CKD and uremic inhibition of LH 
signaling at the level of the Leydig cells (Gungor et al 2010). Yilmaz et al   2011 found that every nmol/L 
decrease in total testosterone concentration in male lead to increase in the percentage (Approximately 22%) of 
cardiovascular risk in the ESRD patients (Yilmaz et al   2011). 
The results of many studies considered the low level of serum testosterone or free testosterone a consequence of 
the changes in gonadal steroid genesis and decreased in synthesis and secretion of testosterone follow the 
progression  of CKD as a result of the hypothalamic–pituitary–testicular axis dysfunction (Gungor et al 2010  & 
Yilmaz et al  2011 & Carrero et al 2010). 
In healthy adult male, testosterone plays important role in lipid metabolism. With the age progressing 
the testosterone level will start decrease which predicts the development of central obesity and accumulation of 
intra-abdominal fat (Allan and McLachlan 2010 &Brand et al             2011).According to the results of many 
studies which have  considered that the metabolic influence of TG and triglyceride rich lipoprotein (TRL) 
remnants which comprise a heterogeneous group of apo B-containing lipoproteins, including chylomicrons, 
VLDLs and IDLs have direct relation to atherogenic state (López-Miranda et al 2004) .The mechanisms of aging 
and death in humans were discussed in many studies and one of their possible explanations that there was 
negative influence of androgens on the lipid profile which is more pronounced in aging men (Kolovou et al 
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2011).One of these studies has attributed the increase in the HDL consumption to the stimulation of reverse 
cholesterol transport (Hersberger et al 2005). 
This hypothesis was supported by Jones et al. 2011 in their recent study by a longer-term testosterone 
replacement therapy (TRT)  demonstrating that after an initial fall in their serum concentrations, HDL-C levels 
returned to baseline levels after 12 month (Jones et al. 2011). 
In end stage renal disease patients there is an increase in  ppTG levels and abnormal prolongation of 
this increase (Montague and Murphy 2009 & Piecha et al 2009 & Attman and Samuelsson 2009 ).The 
disturbance of the clearance of Chylomicrons remnants may underlie this change. However, since Chylomicrons 
compete with TRL of hepatic origin for lipolysis by LPL, the postprandial increase in triglycerides in the 
circulation is worsened by TRL of hepatic origin ( Kaysen 2009). 2Thus, the postprandial increase in TG 
involves not only the metabolism of Chylomicrons of intestinal origin but also the metabolism of TRL of hepatic 
origin (Saland and Ginsberg 2007).  
The general mechanisms underlying the dyslipidemia of renal disease may be  alteration in the  
metabolism of postprandial lipoproteins, alteration in the  metabolism of other TRL, changes in the route of 
reverse cholesterol transport, structural changes of lipoproteins  that mean HDL-C undergoes structural changes 
through the incorporation of serum amyloid A, resulting in the so-called acute phase or inflammatory HDL, 
which act not as protective particles, but as pro-atherogenic particles(Saland and Ginsberg 2007& Kwan et al 
2007& Perrea et al 2008).In chronic kidney  disease there is an increase in pp TG levels and abnormal 
prolongation of this increase (Perrea et al2008 & Badiou et al 2009 & Mesquita et al 2010).  
The clearance of Chylomicrons remnants disturbed. However, since Chylomicrons compete with TRL 
of hepatic origin for lipolysis by LPL, Thus, the postprandial increase in TG involves not only the metabolism of 
Chylomicrons of intestinal origin but also the metabolism of TRL of hepatic origin (Mesquita et al 2010) 
.Supportive observational studies have identified pp TG levels to be a superior predictor of CVD risk compared 
with fasting levels (Mesquita et al 2010 & Nordestgaard et al 2010)..An inverse correlation between testosterone 
and each of ESRD, BMI , total cholesterol and TG was reported (Gungor et al 2010). 
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Tables: 
Table (1):- comparison between ESRD patients and their controls: 
 
P* = 0.05  ,p**= 0.0005  ,   p***=  0.0001 
 
 
          
Parameters 
ESRD (mean ±SD) (n=38) Control(mean ±SD) (n=35) 
Age (yr) 
46.66±10.36 
44.6±8.17 
BMI (kg/m
2
) 26.34±3.91 27.77±2.91 
RBG (mmol/l) 5.74±1.14 5.36±1.12 
pp TG (mmol/l) 2.72±0.65 1.76±0.53
***
 
S. Cholesterol (mmol/l) 5.78±0.68 4.27±0.70
*** 
S. HDL (mmol/l) 0.85±0.13 1.18±0.22
*** 
S. LDL (mmol/l) 3.4 ±0.7 2.96±0.57
***
 
S. VLDL (mmol/l) 1.24±0.3 0.81±0.24
*** 
Ath. index 4.17±1.26 2.6±0.76
*** 
B. Urea (mmol/l) 28.58±10.94 5.85±0.74
*** 
S. Creatinine (µmol/l) 551.0±326.15 74.4±7.79
*** 
S. FSH (IU/l) 10.14±4.24 6.32±1.47
*** 
S. LH (IU/l) 11.78±5.23 5.28±2.1
*** 
S. Total Testosterone (nmol/l) 8.81±3.43 15.17±5.59
*** 
S. SHBG (nmol/L ) 35.5±21.89 32.94±13.52
 
S. Free Testosterone (pmol/l) 20.63±13.89 32.16±13.19 
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Figures: 
 
Figure (1):  Correlation between total   testosterone and   postprandial triglyceride. 
 
 
 
Figure 2:  Correlation between free testosterone, and postprandial triglyceride. 
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